4 transcripts
REGN
Earnings call transcript
NASDAQ
2024 Q2
1 Aug 24
. Despite intense competition, LIBTAYO has maintained its leadership position in non-melanoma skin cancers, while making impressive inroads in non-small cell
REGN
Earnings call transcript
NASDAQ
2024 Q1
2 May 24
the strong performance of our commercial portfolio and future growth opportunity. We continue to strengthen and expand our leadership positions across our
REGN
Earnings call transcript
NASDAQ
2023 Q4
2 Feb 24
to Marion, I would like to add my thanks and appreciation to Bob for his many years of devoted efforts and leaderships, and welcoming and look forward
REGN
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
focus is to maintain and grow Regeneron's anti-VEGF leadership, and we're well positioned to deliver on this goal in an increasingly competitive
- Prev
- 1
- Next